Literature DB >> 10576385

Peritoneal washings cytology combined with immunocytochemical staining in pancreatic cancer.

A Nakao1, K Oshima, S Takeda, T Kaneko, N Kanazumi, S Inoue, S Nomoto, Y Kawase, H Kasuya.   

Abstract

BACKGROUND/AIMS: Peritoneal washings from patients with pancreatic cancer demonstrate malignant cells in 0-58% of patients. But the significance of their potential for implantation and growth after radical surgery has not been clarified.
METHODOLOGY: Peritoneal washings were collected from 74 consecutive pancreatic cancer patients during a 5-year period and studied by conventional staining and immunocytochemical staining using anti-CEA and anti-CA 19-9. Fifty of the 74 patients were resectable and the others were nonresectable.
RESULTS: Seven out of 8 patients with macroscopic peritoneal metastasis were positive in conventional staining, but all 8 patients were positive in immunocytochemical staining. Five of the 66 (8%) patients without macroscopic peritoneal metastasis were positive in conventional staining, but the positive rate increased to 14 of 66 (22%) in immunocytochemical staining. There was no statistically significant difference in post-operative cumulative survival rate between the 13 positive cytology patients and 37 negative cytology patients without macroscopic peritoneal metastasis.
CONCLUSIONS: The positive rate of peritoneal washings cytology was increased in this study by the use of immunocytochemical staining in addition to conventional staining. No statistically significant difference in post-operative cumulative survival rate between positive cytology patients and negative cytology patients without macroscopic peritoneal metastasis was observed.

Entities:  

Mesh:

Year:  1999        PMID: 10576385

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

Review 1.  [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].

Authors:  S Gretschel; A Bembenek; T Schulze; W Kemmner; P M Schlag
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

Review 2.  Oncological problems in pancreatic cancer surgery.

Authors:  Akimasa Nakao; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Shuji Nomoto; Yasuhiro Kodera; Soichiro Inoue; Shin Takeda
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

3.  Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients.

Authors:  Katrin Hoffmann; Christiane Kerner; Wolfgang Wilfert; Marc Mueller; Joachim Thiery; Johann Hauss; Helmut Witzigmann
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 4.  Detection and clinical implications of minimal residual disease in gastro-intestinal cancer.

Authors:  Fabian Wolfrum; Ilka Vogel; Fred Fändrich; Holger Kalthoff
Journal:  Langenbecks Arch Surg       Date:  2005-07-01       Impact factor: 3.445

5.  Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma.

Authors:  R Andersson; C E Vagianos; R C N Williamson
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

6.  Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis.

Authors:  Suguru Yamada; Shin Takeda; Tsutomu Fujii; Shuji Nomoto; Naohito Kanazumi; Hiroyuki Sugimoto; Hideki Kasuya; Yasuhiro Kodera; Tetsuro Nagasaka; Satoshi Morita; Akimasa Nakao
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

7.  Positive Intraoperative Peritoneal Lavage Cytology is a Negative Prognostic Factor in Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Study.

Authors:  Kenichi Hirabayashi; Akiko Imoto; Misuzu Yamada; Atsuko Hadano; Nobuaki Kato; Youko Miyajima; Hitoshi Ito; Yoshiaki Kawaguchi; Toshio Nakagohri; Tetsuya Mine; Naoya Nakamura
Journal:  Front Oncol       Date:  2015-08-07       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.